Loading
Adipokines, Inflammation, and Metabolic Diseases · Journal article
International Journal for Multidisciplinary Research · August 8, 2026
The material analysed did not support any firm read.
This is a narrative review summarizing current understanding of obesity, diabetes, and metabolic syndrome as interrelated metabolic disorders sharing pathophysiological mechanisms. It describes proposed molecular pathways (insulin resistance, inflammation, adipose tissue dysfunction, microbiome changes) and emphasizes the need for integrated prevention and precision medicine approaches, but presents no original data, clinical trials, or evidence synthesis to establish the efficacy or safety of any intervention.
Journal article.
Obesity, diabetes mellitus, and metabolic syndrome are interrelated conditions that often coexist and share common pathophysiological mechanisms Recent research views these disorders as manifestations of metabolic dysregulation involving insulin resistance, chronic inflammation, adipose tissue dysfunction, mitochondrial abnormalities, gut microbiome changes, oxidative stress, and genetic factors Adipose tissue is recognized as an active endocrine organ that secretes substances affecting insulin sensitivity and cardiovascular health
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
The source is a narrative review article without primary data, effect sizes, comparators, or clinical trial evidence; it cannot support clinical decision-making or establish the strength of any intervention.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Metabolic disorders are one of the major public health challenges of the twenty-first century, significantly impacting global morbidity, mortality, and healthcare costs. Obesity, diabetes mellitus, and metabolic syndrome are interrelated conditions that often coexist and share common pathophysiological mechanisms. Recent research views these disorders as manifestations of metabolic dysregulation involving insulin resistance, chronic inflammation, adipose tissue dysfunction, mitochondrial abnormalities, gut microbiome changes, oxidative stress, and genetic factors. The rise in urbanization, sedentary lifestyles, and dietary shifts has increased the prevalence of these disorders, particularly in low- and middle-income countries. Advances in molecular biology and systems medicine have enhanced our understanding of the complex interactions among endocrine, immune, neural, and metabolic pathways in disease progression. Adipose tissue is now recognized as an active endocrine organ that secretes substances affecting insulin sensitivity and cardiovascular health. Additionally, the gut microbiome plays a vital role in regulating metabolism and inflammation. This paper provides an overview of obesity, diabetes mellitus, and metabolic syndrome from an integrated perspective, emphasizing shared molecular pathways, recent therapeutic advancements, and future directions for precision medicine. Understanding the interconnectedness of these disorders is crucial for effective prevention strategies and management approaches to reduce the global burden of metabolic disease.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.